PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech’s founded entity Celea Therapeutics completed a $180 million financing to advance deupirfenidone as a potential new standard of care for IPF. The funding is positioned to support clinical progress toward commercialization, which is generally supportive for the company’s biotech pipeline narrative, though the impact is likely limited to the specific issuer.

Analysis

PureTech’s founded entity Celea Therapeutics completed a $180 million financing to advance deupirfenidone as a potential new standard of care for IPF. The funding is positioned to support clinical progress toward commercialization, which is generally supportive for the company’s biotech pipeline narrative, though the impact is likely limited to the specific issuer.